文献速递骨肌MR

伯明翰非典型软骨肿瘤影像学方案(BACTIP)用于肱骨近端及膝关节周围孤立性中央软骨肿瘤管理的回顾性外部验证研究

A retrospective external validation study of the Birmingham Atypical Cartilage Tumour Imaging Protocol (BACTIP) for the management of solitary central cartilage tumours of the proximal humerus and around the knee.
PubMed 文献 · Eur Radiol · 2024-02-06

回顾性连续纳入123例未治疗中央软骨肿瘤患者,按BACTIP分类并分析肿瘤长度与骨内膜扇贝样改变。BACTIP区分内生软骨瘤与非典型软骨肿瘤的ROC-AUC为0.69,5例ACT和1例II级软骨肉瘤被错误/不安全地建议,可能延误诊断;调整截断值可减少漏诊但增加良性肿瘤过度随访。

要点

  • BACTIP在多数病例中可正确评估肱骨近端及膝关节周围中央软骨肿瘤的初始评估与随访建议。
  • 仅用BACTIP可能漏诊ACT和高grade软骨肉瘤(II级、III级、去分化),使其被排除在专科转诊和进一步随访之外。
  • 骨内膜扇贝样1°截断区分内生软骨瘤与ACT+高grade软骨肉瘤敏感度90%、特异度29%,特异度低导致过度医疗化。

核心结论

  • BACTIP作为肱骨近端、股骨远端和胫骨近端中央软骨肿瘤管理和随访工具具有前景,但5例ACT和1例II级软骨肉瘤被建议出院,可能延误诊断。
  • 调整BACTIP截断值可减少恶性骨肿瘤的潜在诊断延迟,但会增加良性肿瘤不必要的转诊和随访。

研究设计与样本

  • 回顾性/连续性外部验证研究,纳入123例未治疗中央软骨肿瘤患者(45±11岁,37名男性),MRI随访62例、组织病理学确认61例,2003-2020年于根特大学医院/比利时开展。
  • 按BACTIP分类,评估内生软骨瘤、非典型软骨肿瘤(ACT)和高grade软骨肉瘤(II/III级/去分化)之间的肿瘤长度和骨内膜扇贝样改变差异。

关键影像表现/征象

  • 肿瘤长度区分不同中央软骨肿瘤组的ROC-AUC为0.59-0.69(差),骨内膜扇贝样改变为0.73-0.91(尚可-优)。
  • 骨内膜扇贝样改变和BACTIP的诊断性能高于肿瘤长度。

诊断标准与关键数值

  • 骨内膜扇贝样1°截断区分内生软骨瘤与ACT+高grade软骨肉瘤的敏感度为90%、特异度为29%。
  • BACTIP区分内生软骨瘤与ACT的ROC-AUC为0.69(95%CI 0.51-0.87,p=0.041),区分其他中央软骨肿瘤组为0.72-0.81。

临床应用与阅片要点

  • BACTIP在多数病例中可正确进行中央软骨肿瘤的初始评估和随访推荐。
  • 使用BACTIP及调整截断值时,需权衡软骨肉瘤漏诊/潜在诊断延迟与内生软骨瘤过度医疗化之间的利弊。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to externally validate the Birmingham Atypical Cartilage Tumour Imaging Protocol (BACTIP) recommendations for differentiation/follow-up of central cartilage tumours (CCTs) of the proximal humerus, distal femur, and proximal tibia and to propose BACTIP adaptations if the results provide new insights.

METHODS: MRIs of 123 patients (45 ± 11 years, 37 men) with an untreated CCT with MRI follow-up (n = 62) or histopathological confirmation (n = 61) were retrospectively/consecutively included and categorised following the BACTIP (2003-2020 / Ghent University Hospital/Belgium). Tumour length and endosteal scalloping differences between enchondroma, atypical cartilaginous tumour (ACT), and high-grade chondrosarcoma (CS II/III/dedifferentiated) were evaluated. ROC-curve analysis for differentiating benign from malignant CCTs and for evaluating the BACTIP was performed.

RESULTS: For lesion length and endosteal scalloping, ROC-AUCs were poor and fair-excellent, respectively, for differentiating different CCT groups (0.59-0.69 versus 0.73-0.91). The diagnostic performance of endosteal scalloping and the BACTIP was higher than that of lesion length. A 1° endosteal scalloping cut-off differentiated enchondroma from ACT + high-grade chondrosarcoma with a sensitivity of 90%, reducing the potential diagnostic delay. However, the specificity was 29%, inducing overmedicalisation (excessive follow-up). ROC-AUC of the BACTIP was poor for differentiating enchondroma from ACT (ROC-AUC = 0.69; 95%CI = 0.51-0.87; p = 0.041) and fair-good for differentiation between other CCT groups (ROC-AUC = 0.72-0.81). BACTIP recommendations were incorrect/unsafe in five ACTs and one CSII, potentially inducing diagnostic delay. Eleven enchondromas received unnecessary referrals/follow-up.

CONCLUSION: Although promising as a useful tool for management/follow-up of CCTs of the proximal humerus, distal femur, and proximal tibia, five ACTs and one chondrosarcoma grade II were discharged, potentially inducing diagnostic delay, which could be reduced by adapting BACTIP cut-off values.

CLINICAL RELEVANCE STATEMENT: Mostly, Birmingham Atypical Cartilage Tumour Imaging Protocol (BACTIP) assesses central cartilage tumours of the proximal humerus and the knee correctly. Both when using the BACTIP and when adapting cut-offs, caution should be taken for the trade-off between underdiagnosis/potential diagnostic delay in chondrosarcomas and overmedicalisation in enchondromas.

KEY POINTS: • This retrospective external validation confirms the Birmingham Atypical Cartilage Tumour Imaging Protocol as a useful tool for initial assessment and follow-up recommendation of central cartilage tumours in the proximal humerus and around the knee in the majority of cases. • Using only the Birmingham Atypical Cartilage Tumour Imaging Protocol, both atypical cartilaginous tumours and high-grade chondrosarcomas (grade II, grade III, and dedifferentiated chondrosarcomas) can be misdiagnosed, excluding them from specialist referral and further follow-up, thus creating a potential risk of delayed diagnosis and worse prognosis. • Adapted cut-offs to maximise detection of atypical cartilaginous tumours and high-grade chondrosarcomas, minimise underdiagnosis and reduce potential diagnostic delay in malignant tumours but increase unnecessary referral and follow-up of benign tumours.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Van Den Berghe T, Delbare F, Candries E, et al. A retrospective external validation study of the Birmingham Atypical Cartilage Tumour Imaging Protocol (BACTIP) for the management of solitary central cartilage tumours of the proximal humerus and around the knee. Eur Radiol. 2024. PMID: 38319428. doi:10.1007/s00330-024-10604-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。